Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-03-10Clinical Trial Update: A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors [Phase 2]
Phase 2 trial of ladiratuzumab vedotin in multiple advanced solid tumors was terminated, with results posted in March 2025.
-
CLINICAL_TRIALS trial_result · 2025-03-10Clinical Trial Update: A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors [Phase 1]
Phase 1 study of TBio-4101 (TIL) with pembrolizumab in advanced solid tumors has been terminated; the trial includes multiple indications su…
-
CLINICAL_TRIALS trial_result · 2025-03-07Clinical Trial Update: Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC) [Phase 2]
Phase 2 clinical trial update on pixatimod (PG545) plus nivolumab in PD-1 relapsed/refractory metastatic melanoma and non-small cell lung ca…
-
CLINICAL_TRIALS trial_result · 2025-03-07Clinical Trial Update: Savolitinib for Treating Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Patients [Phase 3]
Phase 3 trial update for savolitinib in locally advanced or metastatic non-small cell lung cancer; the study status is completed.
-
FDA approval · 2025-03-07FDA Approved: TAFINLAR — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA supplemental application for TAFINLAR (dabrafenib) submitted by Novartis Pharmaceuticals Corporation to seek changes to the drug's label…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-03-07Clinical Trial Update: Overcoming Resistance to EGFR Neutralization by Combination of Monoclonal Antibodies and Novel Cancer Drugs
A clinical trial studying combinations of monoclonal antibodies with novel cancer drugs to overcome resistance to EGFR neutralization in non…
-
CLINICAL_TRIALS trial_result · 2025-03-07Clinical Trial Update: Phase I/II of Oral Vorinostat Combination With Erlotinib in NSCLC Patients With EGFR Mutations With DP After Erlotinib. [Phase 1, Phase 2]
Phase I/II study of oral vorinostat combined with erlotinib in non-small cell lung cancer patients with EGFR mutations who progressed on erl…
-
CLINICAL_TRIALS research · 2025-03-07Clinical Trial Update: Phase II Clinical Study of Befotertinib in EGFR Non-classical Mutant NSCLC [Phase 2]
Phase II clinical study evaluating Befotertinib in patients with EGFR non-classical mutant non-small cell lung cancer is underway. The trial…
-
CLINICAL_TRIALS research · 2025-03-06Clinical Trial Update: Cerebrospinal Fluid Cytology-guided Intrathecal Chemo-holiday Therapy for EGFR-positive NSCLC Leptomeningeal Metastases [Phase 2]
A Phase 2 clinical trial at Zhejiang Cancer Hospital evaluates cerebrospinal fluid cytology-guided intrathecal chemotherapy with chemo-holid…
-
CLINICAL_TRIALS trial_result · 2025-03-06Clinical Trial Update: MGD019 DART® Protein in Unresectable/Metastatic Cancer [Phase 1]
MGD019, a DART protein from MacroGenics, is being studied in a Phase 1 trial for unresectable/metastatic cancers, including non-small cell l…
-
CLINICAL_TRIALS research · 2025-03-06Clinical Trial Update: Study of LP-184 in Patients With Advanced Solid Tumors [Phase 1, Phase 2]
Lantern Pharma's LP-184 is being studied in a phase 1/2 trial for advanced and metastatic solid tumors, with indications including glioblast…
-
CLINICAL_TRIALS research · 2025-03-06Clinical Trial Update: Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis [NA]
A ClinicalTrials.gov entry describes a study evaluating high-dose furmonertinib in combination with bevacizumab and pemetrexed for EGFR-muta…
-
CLINICAL_TRIALS research · 2025-03-06Clinical Trial Update: Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT [Phase 2]
A Phase 2 clinical trial is evaluating whole-body HER3 quantification using radiolabeled patritumab deruxtecan (HER3-DXd) PET/CT in non-smal…
-
CLINICAL_TRIALS trial_result · 2025-03-05Clinical Trial Update: Phase III Study (Tarceva®) vs Chemotherapy to Treat Advanced Non-Small Cell Lung Cancer in Patients With Mutations in the TK Domain of EGFR [Phase 3]
A Phase III trial comparing Tarceva (erlotinib) to standard chemotherapy in patients with advanced non-small cell lung cancer harboring EGFR…
-
CLINICAL_TRIALS trial_result · 2025-03-05Clinical Trial Update: Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer [Phase 2]
Phase 2 trial evaluating nivolumab with or without ipilimumab or chemotherapy in patients with previously untreated stage I-IIIA non-small c…
-
CLINICAL_TRIALS research · 2025-03-05Clinical Trial Update: Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung Adenocarcinoma [Phase 3]
A Phase 3 trial is planned to compare lorlatinib with concurrent or sequential chemoradiotherapy in stage III ALK-positive non-small cell lu…
-
CLINICAL_TRIALS trial_result · 2025-03-05Clinical Trial Update: Taste and Smell Dysfunction in Patients More Than Two Years After Start of Immune Checkpoint Inhibitor Therapy
The study update reports observations of taste and smell dysfunction occurring more than two years after initiation of immune checkpoint inh…
-
CLINICAL_TRIALS research · 2025-03-05Clinical Trial Update: Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Locally Advanced or Metastatic NSCLC or Solid Tumors With Bone Metastases [Phase 1]
A Phase 1 safety study evaluating a gamma-delta T cell product in combination with low-dose radiotherapy for locally advanced or metastatic …
-
EMA approval · 2025-03-05EMA Authorised: Tarceva (erlotinib) — Cheplapharm Registration GmbH
Tarceva (erlotinib) has been authorised in the EU with Cheplapharm Registration GmbH as the marketing authorisation holder for non-small cel…
-
CLINICAL_TRIALS research · 2025-03-05Clinical Trial Update: The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined with Lenvatinib in NSCLC. [Phase 2]
Phase 2 clinical trial investigating the efficacy and safety of the bispecific anti-PD-1/PD-L1 antibody IBI318 in combination with lenvatini…
-
CLINICAL_TRIALS trial_result · 2025-03-04Clinical Trial Update: Pre-Incisional Ketorolac for Patients Undergoing Surgery for Non-Small Cell Lung Cancer and Renal Cell Carcinoma [Phase 2]
Phase 2 trial evaluating pre-incisional ketorolac in surgery for non-small cell lung cancer or renal cell carcinoma has been terminated, wit…
-
CLINICAL_TRIALS trial_result · 2025-03-04Clinical Trial Update: Safety and Tolerability Evaluation of Sintilimab in Combination With Radiation in Stage IV NSCLC Patients [Phase 1]
Phase 1 trial evaluating safety and tolerability of combining sintilimab with radiotherapy in stage IV non-small cell lung cancer. Results e…
-
CLINICAL_TRIALS research · 2025-03-04Clinical Trial Update: Construction of a Prognostic and Prediction Model for Perioperative Immunotherapy in NSCLC: A Multi - Omics Perspective
This trial aims to construct a multi-omics prognostic and predictive model to guide perioperative immunotherapy in non-small cell lung cance…
-
CLINICAL_TRIALS trial_result · 2025-03-03Clinical Trial Update: NAP in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC [Phase 2]
Phase 2 trial evaluating NAP in combination with docetaxel after obinutuzumab pretreatment in advanced or metastatic non-small cell lung can…
-
CLINICAL_TRIALS research · 2025-03-03Clinical Trial Update: A Prospective Study Investigating the Relationship Between Minimal Residual Disease Detection, Monitoring Frequency, and Prognosis in Non-small Cell Lung Cancer Patients Eligible for Curative Treatment.
A prospective study from Japan will evaluate how detecting minimal residual disease and the frequency of monitoring relate to prognosis in p…